The Wegovy Regime: How the Dosing Schedule Works and What It Asks of You

The dose ladder: what each phase is actually for

Starting at 0.25 mg, the first four weeks of the Wegovy regime are almost entirely about tolerance. At that dose, most people notice little weight change; that is expected. The lower rungs exist so your digestive system can adjust before the doses that do meaningful work. Nausea, the most commonly reported side effect, tends to peak around the transition points and then settle within days to a couple of weeks as your body adapts.

Each subsequent level — 0.5 mg, 1.0 mg, 1.7 mg — is held for approximately four weeks before your prescriber considers moving you up, though that timing is a clinical call, not a rigid rule. The standard maintenance dose is 2.4 mg weekly. The full Wegovy overview on this site covers the licensed indications and what the UK approval covers in more detail. Since January 2026, the MHRA has also approved a 7.2 mg maintenance dose for adults with a BMI of 30 or above, and a single-dose pen for that level followed in April 2026. Whether that higher dose is appropriate for you is a question your prescriber weighs individually; no dose format should be assumed available without clinical confirmation.

The NHS patient guidance for semaglutide, available via the NHS medicines page for semaglutide, sets out what to expect at each stage of the dose schedule in plain terms and is worth reading alongside your patient information leaflet.

What the regime genuinely requires of you day to day

Pick one day a week and keep it. That is the core practical discipline of the Wegovy regime. Injection day can shift by a day or two if something comes up, but erratic timing makes side-effect management harder and muddies your sense of how the medicine is working. Many people anchor it to something fixed, the same morning as a standing appointment, or the evening before a regular rest day.

Food matters too, though not in the way some people expect. Wegovy reduces appetite, sometimes sharply, and the risk that comes with that is not overeating, it is undereating protein and neglecting hydration. Prioritising protein at each meal and drinking enough water throughout the day helps preserve muscle and reduces the fatigue some people notice mid-regime. There is no mandated calorie target attached to the prescription, but the licence specifies that Wegovy is used alongside a reduced-calorie diet and increased physical activity, so those elements are part of the treatment, not optional extras.

If you are wondering how quickly results typically arrive, the guide to how long Wegovy takes to work covers the clinical timeline honestly, including the first few weeks when the scale may barely move.

Stopping, pausing, and what happens to results

This is the decision many people find hardest to think about at the start of a regime, which is exactly why it is worth considering before you begin. The evidence from the STEP 1 trial (published in the New England Journal of Medicine, involving over 1,900 adults) showed that on average, participants regained a substantial portion of lost weight in the year after stopping semaglutide, without sustained lifestyle support. That is not a reason to avoid treatment; it is a reason to go in with realistic expectations and a plan.

NICE recommends semaglutide for a maximum of two years within a specialist weight management framework, though private prescribing operates under the licensed indications rather than NICE's NHS commissioning criteria. Your prescriber reviews your progress at each repeat, at nume, a clinician reads every reorder before it is dispensed, so the regime is never on autopilot.

If results have plateaued or you are considering whether the regime is still working for you, the page on Wegovy and weight loss timelines gives a grounded look at what the evidence says about results at different points. And if you have concerns or doubts about whether continuing is right, the page on Wegovy regrets addresses the questions people often feel awkward raising with a clinic.

Eligibility, cost context, and the private route

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine approval; the prescriber looks at the whole picture, including any contraindications and your current medicines.

NHS access to Wegovy exists but typically involves waiting lists and specialist referral criteria. For people who do not meet the NHS criteria or would rather not wait, a private prescription through a regulated online pharmacy is the main alternative. If cost is a factor in your thinking, the Wegovy price comparison page sets out what private treatment typically costs across the UK market and what those prices do and do not include.

The weight-loss treatment overview covers all the options currently available through a regulated UK prescriber, alongside the broader context of how each medicine fits different starting points. If you are ready to see whether the Wegovy regime is clinically appropriate for you, you can check your eligibility with a free consultation, reviewed the same working day by a GPhC-registered prescriber.